Plain-English translation of NCT06992583 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new cancer treatment called CEA-targeting CAR-T cell therapy for people with advanced lung cancer. The medication works by taking your own immune cells, engineering them in a laboratory to recognize and attack cancer cells, and then putting them back into your body. This study will look at whether the treatment is safe and how well it works.
Advanced lung cancer is difficult to treat, and many patients' cancers stop responding to standard therapies like chemotherapy and immunotherapy. This trial is exploring whether this new type of engineered immune cell therapy could offer hope to patients who have run out of other options.
You likely qualify if…
You likely don't qualify if…
If you join this trial, doctors will collect some of your blood cells through a process called leukapheresis (similar to donating plasma). Your cells will be sent to a laboratory where they are engineered to recognize cancer cells, then grown in larger numbers and given back to you as an infusion into your vein or, if you have fluid around your lungs, directly into that space. You will be monitored closely with blood tests and imaging scans to see how your body responds and whether the treatment is working.
AI-generated summary from trial data · Jul 15, 2026 · Not medical advice
China